The sprawling health-care company dropped $30 billion on its acquisition of Swiss company Actelion last year, so a major deal may not be on the horizon just yet. Still, J&J could use some of the tax law windfall to bulk up its portfolio.
inside third quarter of 2017, Johnson & Johnson held $14 billion overseas, an estimated 0 percent of its total cash, according to Credit Suisse. The company hasn’t shared its plan for the money yet, though which expects to do so before which announces earnings on Jan. 23, a company spokesman told CNBC.
J&J has pointed to acquisitions as an important part of its growth strategy.
“I think the most important thing will be all of the actions we’ve taken to invest inside platforms which we believe have significant growth, along with we’ve been doing This specific both in terms of acquisitions, strategic partnerships along with investing in R&D,” the company’s group worldwide chair, Sandra Peterson, said on an earnings call with analysts in October.
J&J’s focus areas for acquisitions are immunology, oncology, cardiovascular along with metabolic, infectious diseases along with vaccines, along with neuroscience, Credit Suisse analyst Vamil Divan wrote in a note published last month. Investing in single assets at earlier stages of development have been the most value creative moves recently, he added.
So J&J may not be hunting for a blockbuster This specific year, yet which could continue scooping up smaller ones.